Merck KGaA: FDA approves new multiple sclerosis drug
(CercleFinance.com) - US regulators on Friday approved a new multiple sclerosis drug made by Germany's Merck that provides two years of efficacy with just 20 days of oral treatment.
The US Food and Drug Administration (FDA) has approved Mavenclad tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS), the group said.
The drug is the first and only FDA approved treatment for RRMS and active SPMS that provides two years of proven efficacy with a maximum of 20 days of oral treatment, during a two-year period, the German group said.
In the clinical trial program, 81% of patients were free of relapses after two years of short-course oral treatment, compared to 63% of patients who received placebo, Merck noted.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US Food and Drug Administration (FDA) has approved Mavenclad tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS), the group said.
The drug is the first and only FDA approved treatment for RRMS and active SPMS that provides two years of proven efficacy with a maximum of 20 days of oral treatment, during a two-year period, the German group said.
In the clinical trial program, 81% of patients were free of relapses after two years of short-course oral treatment, compared to 63% of patients who received placebo, Merck noted.
Copyright (c) 2019 CercleFinance.com. All rights reserved.